UNITEDHEALTH GROUP INC (UNH) Form 10-Q — Aug 10, 2026
UnitedHealth Group's Q2 2026 net earnings attributable to shareholders jumped 61% year over year to $5.48 billion, with diluted EPS of $6.04 versus $3.74 in Q2 2025, as earnings from operations rose 55% to $8.0 billion. Revenues were essentially flat at $112.0 billion as UnitedHealthcare served 1.6 million fewer people, with Medicare Advantage and Medicaid membership each down 9%; the medical care ratio improved 2.7 points to 86.7% on favorable prior-period reserve development and cost management.
Key figures
- Eps
- 6.04
- Revenue
- 112032
- Net Income
- 5484
- Total Debt
- 73328
- Revenue Yoy
- +0.4% Q2 YoY; +1.2% 1H YoY
- Total Assets
- 309727
- Cash Position
- 28585
- Shares Outstanding
- 897594847
- Units
- USD millions except per-share and share counts
- Tax rate q2
- 18.6% vs 12.5% prior year
- Net income 1h
- 11764
- Diluted eps 1h
- 12.94
- Dispositions 1h
- $1.1B cash received; $211M net gain
- Medicaid members
- 6,780K, -9% YoY
- Adjusted scripts q2
- 387M vs 414M prior year
- Pending acquisition
- $3.0B total; $1.5B cash paid July 2, 2026, $1.5B payable within one year
- Dividend annual rate
- $9.28 per share (raised from $8.84 in June 2026)
- Share repurchases 1h
- 10.5 million shares at $344.08 average, including 6.4M via forward contracts at $312.73
- Medical care ratio q2
- 86.7% vs 89.4% prior year
- Q2 dividend per share
- 2.32
- Total medical members
- 48,525K, -3% YoY
- Operating cash flow 1h
- 19964
- Medicare advantage members
- 7,565K, -9% YoY
- Earnings from operations q2
- 7991
- Forward repurchase settlement
- $2.0B settled July 1, 2026
- Buyback authorization remaining
- 10.6 million shares as of June 30, 2026
- Earnings from operations q2 yoy
- +55%
- South america fx losses in hfs remeasurement
- 893
Price after filing
Close on the filing date to close N calendar days later (from $408.74). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.